Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever ...

CEO Stephane Bancel has bought stock for the first time on the open market since he was named the top executive in October ...

Short sellers increased their bets against the broader healthcare sector in February vs. January, and Moderna remained the ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

Moderna est attendu en nette hausse en pré-marché après que le PDG Stéphane Bancel et l’administrateur Paul Sagan ont acheté ...

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

Moderna (MRNA) stock in focus as the company aims a 2027 marketing nod for Merck (MRK) partnered skin cancer vaccine. Read ...

In a couple of regulatory filings with the SEC, it was revealed that Moderna’s CEO Stephane Bancel and director Paul Sagan acquired common stock worth $6 million. On Monday, Bancel acquired ...

Wall Street rebondit grâce à l'exemption de droits de douane sur les véhicules La Bourse de New York a terminé en hausse ...

Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market.

(AOF) - Moderna est attendu en nette hausse en pré-marché après que le PDG Stéphane Bancel et l’administrateur Paul Sagan ont acheté pour 6 millions de dollars d’actions de la société.